CDE Detailed Report
Disease: content
Subdomain Name: Drugs
CRF: welcome
Displaying 1 - 27 of 27
Subdomain Name: Drugs
CRF: welcome
Displaying 1 - 27 of 27
| CDE ID | CDE Name | Variable Name | Definition | Short Description | Question Text | Permissible Values | Description | Data Type | Disease Specific Instructions | Disease Specific Reference | Population | Classification (e.g., Core) | Version Number | Version Date | CRF Name (CRF Module / Guidance) | Subdomain Name | Domain Name | Size | Input Restrictions | Min Value | Max Value | Measurement Type | External Id Loinc | External Id Snomed | External Id caDSR | External Id CDISC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C58955 | Antihypertensive agent stroke discharge prescribe other text | AntihyptAgStrkDischrgPrscrbOTH | The free-text field related to 'Antihypertensive agent stroke discharge prescribe type', specifying other text | The free-text field related to 'Antihypertensive agent stroke discharge prescribe type', specifying other text | Other, specify | Alphanumeric |
No instructions available |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 16:12:46.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C58956 | Anti diabetic agent stroke discharge prescribe type | AntiDbtcAgStrkDischrgPrscrbTyp | Type(s) of anti-diabetic agents prescribed at discharge following stroke | Type(s) of anti-diabetic agents prescribed at discharge following stroke | IF anti-diabetic agents prescribed, specify type(s) | Insulin;Amylin analogs (Pramlintide);Sulfonylureas (glimepiride, glipizide, glyburide, others);Meglitinides (nateglinide, repaglinide);Biguanides (metformin);Thiazolidinediones (pioglitazone, rosiglitazone);Alpha-glucosidase inhibitors (acarbose, miglitol);Dipeptidyl peptidase inhibitors (alogliptin, linagliptin, others);Sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin, others);Oral combination drugs;Other, specify | Insulin;Amylin analogs (Pramlintide);Sulfonylureas (glimepiride, glipizide, glyburide, others);Meglitinides (nateglinide, repaglinide);Biguanides (metformin);Thiazolidinediones (pioglitazone, rosiglitazone);Alpha-glucosidase inhibitors (acarbose, miglitol);Dipeptidyl peptidase inhibitors (alogliptin, linagliptin, others);Sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin, others);Oral combination drugs;Other, specify | Alphanumeric |
Choose all that apply. |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 16:13:44.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C58957 | Anti diabetic agent stroke discharge prescribe other text | AntiDbtcAgStrkDischrgPrscrbOTH | The free-text field related to 'Anti diabetic agent stroke discharge prescribe type', specifying other text | The free-text field related to 'Anti diabetic agent stroke discharge prescribe type', specifying other text | Other, specify | Alphanumeric |
No instructions available |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 16:34:09.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C58845 | Discharge origin location type | DischargeOriginLocTyp | The type of origin location that is discharging the participant/subject | The type of origin location that is discharging the participant/subjec | Specify discharging location | Intensive Inpatient rehabilitation facility (IRF) including distinct rehabilitation units of a hospital: three hours or greater of therapy per day;Acute hospital;Medicare certified long-term care hospital (LTCH);Hospice- home or medical facility providing hospice level of care;Other not defined above:;Skilled nursing facility (SNF)/ subacute rehab: less than two hours a day of therapy | Intensive Inpatient rehabilitation facility (IRF) including distinct rehabilitation units of a hospital: three hours or greater of therapy per day;Acute hospital;Medicare certified long-term care hospital (LTCH);Hospice- home or medical facility providing hospice level of care;Other not defined above:;Skilled nursing facility (SNF)/ subacute rehab: less than two hours a day of therapy | Alphanumeric |
No instructions available |
No references available | Adult;Pediatric | Supplemental | 1.00 | 2020-05-17 18:41:28.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Single Pre-Defined Value Selected |
||||||||
| C58958 | Lipid lower agent stroke discharge prescribe type | LipidLowAgStrkDischrgPrscrbTyp | Type(s) of lipid lowering agents prescribed at discharge following stroke | Type(s) of lipid lowering agents prescribed at discharge following stroke | IF lipid lowering agents prescribed, specify type(s) | Statin (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin);PCSK9 inhibitors (alirocumab, evolocumab);Selective cholesterol absorption inhibitors (ezetimibe);Bile acid sequestrants (cholestyramine, colestipol, colesevelam);Fibrates (gemfibrozil, fenofibrate, clofibrate);Niacin;Omega-3 fatty acid ethyl esters (Lovaza, Vascepa);Marine-derived omega-3 polyunsaturated fatty acids;Other, specify | Statin (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin);PCSK9 inhibitors (alirocumab, evolocumab);Selective cholesterol absorption inhibitors (ezetimibe);Bile acid sequestrants (cholestyramine, colestipol, colesevelam);Fibrates (gemfibrozil, fenofibrate, clofibrate);Niacin;Omega-3 fatty acid ethyl esters (Lovaza, Vascepa);Marine-derived omega-3 polyunsaturated fatty acids;Other, specify | Alphanumeric |
Choose all that apply. |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 16:35:08.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C58846 | Discharge origin location other text | DischargeOriginLocOTH | The free-text field related to 'Discharge origin location type', specifying other text | The free-text field related to 'Discharge origin location type', specifying other text | Other not defined above | Alphanumeric |
No instructions available |
No references available | Adult;Pediatric | Supplemental | 1.00 | 2020-05-18 07:54:34.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C58959 | Lipid lower agent stroke discharge prescribe other text | LipidLowAgStrkDischrgPrscrbOTH | The free-text field related to 'Lipid lower agent stroke discharge prescribe type', specifying other text | The free-text field related to 'Lipid lower agent stroke discharge prescribe type', specifying other text | Other, specify | Alphanumeric |
No instructions available |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 16:40:56.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C58949 | Medication stroke discharge prescribe category | MedctnStrkDischrgPrscrbCat | Class(es) of medications the participant/subject was prescribed at discharge following stroke | Class(es) of medications the participant/subject was prescribed at discharge following stroke | Which class(es) of medications was the participant/subject prescribed at discharge | Anticoagulant agents;Antiplatelet agents;Antihypertensive agents;Anti-diabetic agents;Lipid lowering agents | Anticoagulant agents;Antiplatelet agents;Antihypertensive agents;Anti-diabetic agents;Lipid lowering agents | Alphanumeric |
Choose all that apply. |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 15:34:45.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C58960 | Antithrombotic therapy not prescribed serious side effect text | AntithromThrNotPrsSrSdeEfctTxt | The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying serious side effect to medication text | The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying serious side effect to medication text | Serious side effect to medication, specify | Alphanumeric |
Choose all that apply. If reasons are not mentioned in the context of antithrombotics, do not make inferences (e.g., do not assume that antithrombotics are not being prescribed because of a bleeding disorder unless documentation explicitly states so). |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry | Adult;Pediatric | Supplemental | 1.00 | 2020-07-29 16:42:04.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C58950 | Anticoagulant agent stroke discharge prescribe type | AnticoagAgStrkDischrgPrscrbTyp | Type(s) of anticoagulant agents prescribed at discharge following stroke | Type(s) of anticoagulant agents prescribed at discharge following stroke | IF anticoagulant agents prescribed, specify type(s) | Other, specify;Low molecular weight heparin (LMWH) (Enoxaparin, others);Warfarin (Coumadin);Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) | Other, specify;Low molecular weight heparin (LMWH) (Enoxaparin, others);Warfarin (Coumadin);Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) | Alphanumeric |
Choose all that apply. |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 15:42:35.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C58951 | Anticoagulant agent stroke discharge prescribe other text | AnticoagAgStrkDischrgPrscrbOTH | The free-text field related to 'Anticoagulant agent stroke discharge prescribe type', specifying other text | The free-text field related to 'Anticoagulant agent stroke discharge prescribe type', specifying other text | Other, specify | Alphanumeric |
No instructions available |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 15:54:08.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C58952 | Antiplatelet agent stroke discharge prescribe type | AntiplatAgStrkDischrgPrscrbTyp | Type(s) of antiplatelet agents prescribed at discharge following stroke | Type(s) of antiplatelet agents prescribed at discharge following stroke | IF antiplatelet agents prescribed, specify type(s) | Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Cilostazol;Other, specify | Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Cilostazol;Other, specify | Alphanumeric |
Choose all that apply. |
Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH [published correction appears in J Thromb Haemost. 2015;13(8):1539]. J Thromb Haemost. 2015;13(6):1154-1156.<br /><br />Kim BJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LKS, Yu S, Hwang YH, Lee JS, Lee J, Rha JH, Heo SH, Ahn SH, Seo WK, Park JM, Lee JH, Kwon JH, Sohn SI, Jung JM, Navarro JC, Kim HY, Kim EG, Kim S, Cha JK, Park MS, Nam HS, Kang DW; PICASSO Investigators. Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial. Stroke. 2020 Mar;51(3):931-937. | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 15:56:47.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C58953 | Antiplatelet agent stroke discharge prescribe other text | AntiplatAgStrkDischrgPrscrbOTH | The free-text field related to 'Antiplatelet agent stroke discharge prescribe type', specifying other text | The free-text field related to 'Antiplatelet agent stroke discharge prescribe type', specifying other text | Other, specify | Alphanumeric |
No instructions available |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 16:02:18.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C58954 | Antihypertensive agent stroke discharge prescribe type | AntihyptAgStrkDischrgPrscrbTyp | Type(s) of antihypertensive agents prescribed at discharge following stroke | Type(s) of antihypertensive agents prescribed at discharge following stroke | IF antihypertensive agents prescribed, specify type(s) | Beta-blocker (atenolol, metoprolol, propranolol, others);Combined alpha and beta-blocker (carvedilol, labetalol);Calcium channel blocker (amlodipine, diltiazem, nifedipine, verapamil, others);Diuretic (chlorothiazide, hydrochlorothiazide, chlorthalidone, others);ACE-inhibitor (enalaopril, lisinopril, ramipril, others);Angiotensin II receptor blocker (candesartan, losartan, valsartan, others);Alpha blocker (doxazosin, prazosin, terazosin);Central agonist (alpha methyldopa, clonidine, others);Other, specify | Beta-blocker (atenolol, metoprolol, propranolol, others);Combined alpha and beta-blocker (carvedilol, labetalol);Calcium channel blocker (amlodipine, diltiazem, nifedipine, verapamil, others);Diuretic (chlorothiazide, hydrochlorothiazide, chlorthalidone, others);ACE-inhibitor (enalaopril, lisinopril, ramipril, others);Angiotensin II receptor blocker (candesartan, losartan, valsartan, others);Alpha blocker (doxazosin, prazosin, terazosin);Central agonist (alpha methyldopa, clonidine, others);Other, specify | Alphanumeric |
Choose all that apply. |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 1.00 | 2020-07-29 16:03:33.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C18986 | Extracranial venous thromboembolism other text | ExtraCranVenThromOTH | The free-text field related to 'Extracranial venous thromboembolism type', specifying other text | The free-text field related to 'Extracranial venous thromboembolism type', specifying other text | Other, specify | Alphanumeric |
Choose all that apply. |
No references available | Adult;Pediatric | Supplemental | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C14629 | Anticoagulant agent in hospital indicator | AnticoagAgentInHospInd | Whether the participant/subject received anticoagulant agents during the acute hospital stay, not including venous prophylaxis dose Unfractionated heparin, LMW heparin, etc | Whether the participant/subject received anticoagulant agents during the acute hospital stay, not including venous prophylaxis dose Unfractionated heparin, LMW heparin, etc. | Did the participant/subject receive anticoagulant agents | Yes;No;Unknown | Yes;No;Unknown | Alphanumeric |
Choose one |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en | Adult;Pediatric | Supplemental-Highly Recommended | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Single Pre-Defined Value Selected |
||||||||
| C18987 | Extracranial venous thromboembolism prophylaxis other text | ExtraCranVenThromProphylOTH | The free-text field related to 'Extracranial venous thromboembolism prophylaxis type', specifying other text | The free-text field related to 'Extracranial venous thromboembolism prophylaxis type', specifying other text | Other, specify | Alphanumeric |
Choose all that apply. |
CMS/ The Joint Commission: SCIP-VTE-1, SCIP-VTE-2; The Joint Commission Only: STK-1, VTE-1 | Adult;Pediatric | Supplemental | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C14630 | Anticoagulant agent in hospital type | AnticoagAgentInHospTyp | Type(s) of anticoagulant agents received during the acute hospital stay | Type(s) of anticoagulant agents received during the acute hospital stay | IF YES, type(s) of anticoagulant agents received | Unfractionated heparin IV;Full dose LMW heparin (Enoxaparin, Others);Warfarin (Coumadin);Other, specify;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) | Unfractionated heparin IV;Full dose LMW heparin (Enoxaparin, Others);Warfarin (Coumadin);Other, specify;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) | Alphanumeric |
Choose all that apply. |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry | Adult;Pediatric | Supplemental-Highly Recommended | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C18988 | Antithrombotic therapy not prescribed other text | AntithromTherNotPresOTH | The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying other text | The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying other text | Other, specify | Alphanumeric |
Choose all that apply. If reasons are not mentioned in the context of antithrombotics, do not make inferences (e.g., do not assume that antithrombotics are not being prescribed because of a bleeding disorder unless documentation explicitly states so). |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry | Adult;Pediatric | Supplemental | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C14631 | Antiplatelet agent in hospital indicator | AntiplatelAgentInHospInd | Whether the participant/subject received antiplatelet agents during the acute hospital stay | Whether the participant/subject received antiplatelet agents during the acute hospital stay | Did the participant/subject receive antiplatelet agents | Yes;No;Unknown | Yes;No;Unknown | Alphanumeric |
Choose one |
No references available | Adult;Pediatric | Supplemental-Highly Recommended | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Single Pre-Defined Value Selected |
||||||||
| C14632 | Antiplatelet agent in hospital type | AntiplatAgentInHospTyp | Type(s) of antiplatelet agents received during the acute hospital stay | Type(s) of antiplatelet agents received during the acute hospital stay | IF YES, type(s) of antiplatelet agents received | Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Other, specify;Cilostazol | Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Other, specify;Cilostazol | Alphanumeric |
Choose all that apply. |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry<br /><br />Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH [published correction appears in J Thromb Haemost. 2015;13(8):1539]. J Thromb Haemost. 2015;13(6):1154-1156.<br /><br />Kim BJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LKS, Yu S, Hwang YH, Lee JS, Lee J, Rha JH, Heo SH, Ahn SH, Seo WK, Park JM, Lee JH, Kwon JH, Sohn SI, Jung JM, Navarro JC, Kim HY, Kim EG, Kim S, Cha JK, Park MS, Nam HS, Kang DW; PICASSO Investigators. Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial. Stroke. 2020 Mar;51(3):931-937. | Adult;Pediatric | Supplemental-Highly Recommended | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C14633 | Extracranial venous thromboembolism indicator | ExtraVenThromInd | Whether the participant/ subject was diagnosed with an extracranial venous thromboembolism (VTE) | Whether the participant/ subject was diagnosed with an extracranial venous thromboembolism (VTE) | Was the participant/subject diagnosed with VTE | Yes;No;Unknown | Yes;No;Unknown | Alphanumeric |
Choose one |
No references available | Adult;Pediatric | Supplemental | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Single Pre-Defined Value Selected |
||||||||
| C14634 | Extracranial venous thromboembolism type | ExtraCranVenThromTyp | Type(s) of extracranial venous thromboembolism (VTE) diagnosed with | Type(s) of extracranial venous thromboembolism (VTE) diagnosed with | IF YES, diagnosis with which type(s) | Deep venous thrombosis (DVT);Pulmonary embolism;Other, specify | Deep venous thrombosis (DVT);Pulmonary embolism;Other, specify | Alphanumeric |
Choose all that apply. |
No references available | Adult;Pediatric | Supplemental | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C14635 | Extracranial venous thromboembolism prophylaxis type | ExtraCranVenThromProphylTyp | Type(s) of extracranial venous thromboembolism (VTE) prophylaxis used | Type(s) of extracranial venous thromboembolism (VTE) prophylaxis used | IF YES, type(s) of VTE prophylaxis used | Low dose unfractionated heparin (LDUH);Low molecular weight heparin (LMWH);Intermittent pneumatic compression devices (IPC);Other, specify;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) | "regular" heparin;enoxaparin, dalteparin, nadroparin, danaparoid, heparinoids, etc.;;;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) | Alphanumeric |
Choose all that apply. |
CMS/ The Joint Commission: SCIP-VTE-1, SCIP-VTE-2; The Joint Commission Only: STK-1, VTE-1 | Adult;Pediatric | Supplemental | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C14638 | Antithrombotic therapy not prescribed reason | AntithromTherNotPresRsn | Reason(s) for not prescribing antithrombotic therapy (i.e., no anticoagulant or antiplatelet agents), documented by a physician, advance practice nurse or physician assistant | Reason(s) for not prescribing antithrombotic therapy (i.e., no anticoagulant or antiplatelet agents), documented by a physician, advance practice nurse or physician assistan | Reason(s) antithrombotic therapy was not prescribed at discharge | Allergy to aspirin, clopidogrel, dipyridamole, cilostazol, warfarin, direct thrombin inhibitor, factor Xa inhibitor or heparin (history or current);Patient/Family refused;Risk for bleeding;Discontinued due to bleeding;Serious side effect to medication, specify;Terminal illness/Comfort measures only;Other, specify | Allergy to aspirin, clopidogrel, dipyridamole, cilostazol, warfarin, direct thrombin inhibitor, factor Xa inhibitor or heparin (history or current);Patient/Family refused;Risk for bleeding;Discontinued due to bleeding;Serious side effect to medication, specify;Terminal illness/Comfort measures only;Other, specify | Alphanumeric |
Choose all that apply. If reasons are not mentioned in the context of antithrombotics, do not make inferences (e.g., do not assume that antithrombotics are not being prescribed because of a bleeding disorder unless documentation explicitly states so). |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry | Adult;Pediatric | Supplemental | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data |
Multiple Pre-Defined Values Selected |
||||||||
| C18984 | Anticoagulant agent in hospital other text | AnticoagAgentInHospOTH | The free-text field related to 'Anticoagulant agent in hospital type', specifying other text | The free-text field related to 'Anticoagulant agent in hospital type', specifying other text | Other, specify | Alphanumeric |
Choose all that apply. |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry | Adult;Pediatric | Supplemental-Highly Recommended | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
|||||||||
| C18985 | Antiplatelet agent in hospital other text | AntiplatAgentInHospOTH | The free-text field related to 'Antiplatelet agent in hospital type', specifying other text | The free-text field related to 'Antiplatelet agent in hospital type', specifying other text | Other, specify | Alphanumeric |
Choose all that apply. |
American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry | Adult;Pediatric | Supplemental-Highly Recommended | 3.00 | 2013-06-21 00:00:00.0 | Antithrombotics and Risk Factor Controlling Medications | Drugs | Treatment/Intervention Data | 4000 |
Free-Form Entry |
